Vaccine design based on 16 epitopes of SARS-CoV-2 spike protein

J Med Virol. 2021 Apr;93(4):2115-2131. doi: 10.1002/jmv.26596. Epub 2020 Nov 1.

Abstract

The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) urgently requires an effective vaccine for prevention. In this study, 66 epitopes containing pentapeptides of SARS-CoV-2 spike protein in the IEDB database were compared with the amino acid sequence of SARS-CoV-2 spike protein, and 66 potentially immune-related peptides of SARS-CoV-2 spike protein were obtained. Based on the single-nucleotide polymorphisms analysis of spike protein of 1218 SARS-CoV-2 isolates, 52 easily mutated sites were identified and used for vaccine epitope screening. The best vaccine candidate epitopes in the 66 peptides of SARS-CoV-2 spike protein were screened out through mutation and immunoinformatics analysis. The best candidate epitopes were connected by different linkers in silico to obtain vaccine candidate sequences. The results showed that 16 epitopes were relatively conservative, immunological, nontoxic, and nonallergenic, could induce the secretion of cytokines, and were more likely to be exposed on the surface of the spike protein. They were both B- and T-cell epitopes, and could recognize a certain number of HLA molecules and had high coverage rates in different populations. Moreover, epitopes 897-913 were predicted to have possible cross-immunoprotection for SARS-CoV and SARS-CoV-2. The results of vaccine candidate sequences screening suggested that sequences (without linker, with linker GGGSGGG, EAAAK, GPGPG, and KK, respectively) were the best. The proteins translated by these sequences were relatively stable, with a high antigenic index and good biological activity. Our study provided vaccine candidate epitopes and sequences for the research of the SARS-CoV-2 vaccine.

Keywords: SARS-CoV-2; epitope; non-synonymous mutation; spike protein; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • COVID-19 / virology*
  • COVID-19 Vaccines / immunology*
  • Computational Biology
  • Epitopes, B-Lymphocyte / immunology*
  • Epitopes, T-Lymphocyte / immunology*
  • Humans
  • Immunogenicity, Vaccine
  • SARS-CoV-2 / immunology*
  • Spike Glycoprotein, Coronavirus / immunology*

Substances

  • COVID-19 Vaccines
  • Epitopes, B-Lymphocyte
  • Epitopes, T-Lymphocyte
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2